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A B S T R A C T
Cocoa is rich in polyphenols, a subgroup of dietary flavonoids, which seems to be 
able to reduce cardiovascular risk. Since dark chocolate is popular in Europe and 
the United States, and it is a potent source of polyphenols, there is increasing interest 
on its potential effects on cardiovascular risk. Evidence suggests that dark chocolate 
has some beneficial effects on cardiovascular risk factors, particularly on atherogenic 
dyslipidemia. Beneficial effects include the reduction of elevated blood pressure in hy-
pertensive subjects, the increase in vasodilatation with improved endothelial function, 
as well as the inhibition of platelet activation and function. In addition, dark chocolate 
seems to reduce C-reactive protein concentrations and to modulate atherogenic dys-
lipidemia, reducing plasma total-cholesterol, LDL-cholesterol and triglyceride levels, 
with a concomitant increase in HDL-cholesterol concentrations. Yet, further studies 
are needed before recommending habitual dark chocolate consumption for the reduc-
tion of cardiovascular risk.
I N T R O D U C T I O N
Dark chocolate is a potent source of flavonoids, which have been proposed as a 
key protective dietary component able to reduce cardiovascular risk.1 These agents 
are polyphenolic compounds ubiquitous in fruits and vegetables, and appear in higher 
concentrations in the form of flavonols in cocoa, with beneficial antioxidant effects.2,3 
In addition, flavonoids are known to suppress inflammation, by inhibiting the cyclo-
oxygenase-2, an enzyme that up-regulates during inflammation, as well as some types 
of tumor formation.4 Recent evidence also suggests that some flavanols may inhibit 
atherogenesis, by the interaction with beta-platelet derived growth factor.5
Further beneficial effects include the reduction of elevated blood pressure in hyper-
tensive subjects,6,7 the increase in vasodilatation with improved endothelial function,8,9 
as well as the inhibition of platelet activation and function.10 In addition, dark chocolate 
seems to reduce C-reactive protein concentrations11 and to modulate atherogenic dys-
lipidemia, reducing plasma total-cholesterol, low-density lipoprotein (LDL)-cholesterol 
and triglyceride levels,11,12 with a concomitant increase in high-density lipoprotein 
(HDL)-cholesterol concentrations.11,12 This represents a very important point, since 
atherogenic dyslipidemia is strongly associated with cardiovascular risk.13
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D A R K  C H O C O L A T E ,  O X I D A T I O N  
A N D  A T H E R O G E N I C  D Y S L I P I D E M I A
It is difficult to determine which compounds present 
in the dark chocolate affect plasma lipids, and particularly 
HDL-cholesterol levels;14 future studies should identify the 
HDL-increasing compound in cocoa. The modifications on 
LDL-cholesterol are of high interest as well, but definitive 
conclusions are difficult to make so far. The most reasonable 
explanation is that oxidative modifications of LDL play a key 
role in the initial stages of atherogenesis and dark chocolate 
is able to reduce LDL oxidative susceptibility, increasing total 
antioxidant capacity.
In fact, the most important link between lipid metabolism 
and inflammation is based on the formation of foam cells 
(first step of plaque generation) from altered, oxidized LDL.15 
Yet, LDL are very heterogeneous particles, which comprise 
multiple distinct subclasses that differ in size, density, physi-
cochemical composition, metabolic and oxidative behavior, as 
well as atherogenicity, with at least 4 major subspecies: large 
LDL-I, medium LDL-II, small LDL-III, and very small LDL-
IV (Figure 1).16 Increasing evidence suggests that the ‘‘quality’’ 
of LDL has a direct influence on cardiovascular risk, with 
smaller, more dense LDL particles being more susceptible to 
oxidation and greatly atherogenic.17,18
Oxidative stress plays a crucial role in the atherogenic 
process.19 The increase in reactive oxygen species leads to the 
formation of oxidized (ox) LDL particles. Strong evidence sup-
port the hypothesis that oxLDL are highly immunogenic and 
more atherogenic compared to the normal LDL molecules. 
Reactive oxygen species are generated through several meta-
bolic pathways. These cascades act as modifiers in fatty acids, 
lipoproteins and amino acids, resulting thus in the formation 
of atherogenic particles such as oxLDL.20
C O N C L U S I O N S
Cocoa is rich in polyphenols, a subgroup of dietary flavo-
noids, which seem to be able to reduce cardiovascular risk. 
Since dark chocolate is popular in Europe and the United 
States, and it is a potent source of polyphenols, there is in-
creasing interest on its potential effects on cardiovascular risk. 
Evidence suggests that dark chocolate has some beneficial 
effects on cardiovascular risk factors, particularly on athero-
genic dyslipidemia. Yet, further studies are needed before 
recommending habitual dark chocolate consumption for the 
reduction of cardiovascular risk.
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sity (as modified from ref. 16). CAD: coronary artery disease.
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